Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Clinical Drug Investigation
|
February 25, 2015
The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin
Júlio Fonseca, Carlos Martins da Silva
Clinical Drug Investigation
|
February 25, 2015
The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia by primary care family physicians in Portugal
Júlio Fonseca, Carlos Martins da Silva
Current Opinion in Urology
|
May 16, 2009
Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
Carlos Martins da Silva, Francisco Cruz
International Journal of Urology : Official Journal of the Japanese Urological Association
|
May 3, 2013
Botulinum toxin treatment for bladder dysfunction
André Santos-Silva, Carlos Martins da Silva, Francisco Cruz
Toxicon : Official Journal of the International Society on Toxinology
|
August 4, 2015
Use of botulinum toxin for genitourinary conditions: What is the evidence?
Carlos Martins da Silva, Michael B Chancellor, Christopher Patrick Smith, et al.
Clinical Drug Investigation
|
October 20, 2022
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Arnaldo Figueiredo, Luís Costa, Maria Joaquina Maurício, et al.
Clinical Drug Investigation
|
July 13, 2022
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Arnaldo Figueiredo, Luís Costa, Maria Joaquina Maurício, et al.
Clinical Drug Investigation
|
January 27, 2023
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Arnaldo Figueiredo, Luís Costa, Maria Joaquina Maurício, et al.
BJU International
|
April 17, 2012
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide
Karol Axcrona, Sirpa Aaltomaa, Carlos Martins da Silva, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Clinical Drug Investigation
|
February 25, 2015
The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin
Júlio Fonseca, Carlos Martins da Silva
Clinical Drug Investigation
|
February 25, 2015
The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia by primary care family physicians in Portugal
Júlio Fonseca, Carlos Martins da Silva
Current Opinion in Urology
|
May 16, 2009
Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
Carlos Martins da Silva, Francisco Cruz
International Journal of Urology : Official Journal of the Japanese Urological Association
|
May 3, 2013
Botulinum toxin treatment for bladder dysfunction
André Santos-Silva, Carlos Martins da Silva, Francisco Cruz
Toxicon : Official Journal of the International Society on Toxinology
|
August 4, 2015
Use of botulinum toxin for genitourinary conditions: What is the evidence?
Carlos Martins da Silva, Michael B Chancellor, Christopher Patrick Smith, et al.
Clinical Drug Investigation
|
October 20, 2022
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Arnaldo Figueiredo, Luís Costa, Maria Joaquina Maurício, et al.
Clinical Drug Investigation
|
July 13, 2022
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Arnaldo Figueiredo, Luís Costa, Maria Joaquina Maurício, et al.
Clinical Drug Investigation
|
January 27, 2023
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Arnaldo Figueiredo, Luís Costa, Maria Joaquina Maurício, et al.
BJU International
|
April 17, 2012
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide
Karol Axcrona, Sirpa Aaltomaa, Carlos Martins da Silva, et al.
Page
of 1